Paper36910854
Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.
Chen N and 2 others. Chin J Cancer Res, 2023. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment. Papers, record 36910854. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36910854
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16123223 | Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. | Blood | 2005 | https://conductscience.org/library/papers/16123223 | PubMed |
| 2 | 25167226 | Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. | Br J Cancer | 2014 | https://conductscience.org/library/papers/25167226 | PubMed |
| 3 | 12932382 | Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. | Lancet | 2003 | https://conductscience.org/library/papers/12932382 | PubMed |
| 4 | 22857859 | Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. | Radiother Oncol | 2012 | https://conductscience.org/library/papers/22857859 | PubMed |
| 5 | 19631287 | Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. | Clin Gastroenterol Hepatol | 2010 | https://conductscience.org/library/papers/19631287 | PubMed |
| 6 | 9586910 | Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. | J Clin Oncol | 1998 | https://conductscience.org/library/papers/9586910 | PubMed |
| 7 | 18407433 | Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. | Int J Radiat Oncol Biol Phys | 2008 | https://conductscience.org/library/papers/18407433 | PubMed |
| 8 | 7783535 | Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. | Lancet | 1995 | https://conductscience.org/library/papers/7783535 | PubMed |
| 9 | 21287530 | Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. | Cancer | 2011 | https://conductscience.org/library/papers/21287530 | PubMed |
| 10 | 29861116 | Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29861116 | PubMed |
| 11 | 1548520 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. | J Clin Oncol | 1992 | https://conductscience.org/library/papers/1548520 | PubMed |
| 12 | 9112461 | Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. | Int J Radiat Oncol Biol Phys | 1997 | https://conductscience.org/library/papers/9112461 | PubMed |
| 13 | 26374429 | Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. | J Natl Cancer Inst | 2015 | https://conductscience.org/library/papers/26374429 | PubMed |
| 14 | 27029228 | First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. | Lancet Haematol | 2014 | https://conductscience.org/library/papers/27029228 | PubMed |
| 15 | 16324817 | Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. | Eur J Surg Oncol | 2006 | https://conductscience.org/library/papers/16324817 | PubMed |
| 16 | 15569109 | Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. | Aliment Pharmacol Ther | 2004 | https://conductscience.org/library/papers/15569109 | PubMed |
| 17 | 1682595 | Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. | Lancet | 1991 | https://conductscience.org/library/papers/1682595 | PubMed |
| 18 | 26742109 | ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. | Neuroendocrinology | 2016 | https://conductscience.org/library/papers/26742109 | PubMed |
| 19 | 15752894 | Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. | Int J Radiat Oncol Biol Phys | 2005 | https://conductscience.org/library/papers/15752894 | PubMed |
| 20 | 29566109 | Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/29566109 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42649986 | Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649986 | PubMed |
| 40042008 | Associations of Social Vulnerability and Race-Ethnicity With Gastrointestinal Cancers in the United States. | Cancer Med | 2025 | https://conductscience.org/library/papers/40042008 | PubMed |
| 39958355 | A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients. | Front Immunol | 2025 | https://conductscience.org/library/papers/39958355 | PubMed |
| 38751434 | Distal margin distance in radical resection of locally advanced rectal cancer after neoadjuvant therapy. | Chin J Cancer Res | 2024 | https://conductscience.org/library/papers/38751434 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36910854
GET https://conductscience.org/api/papers/v1/36910854/references?page=2